GoAI
Get started
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc.

OVID

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.80

+$0.06 · +2.19%

Aug 21, 4:00 PM ET

OVID company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

2

Overpriced

Momentum

60

Neutral

Sentiment

62

Bullish

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Margaret Alexander
Listed since
May 5, 2017
Employees
23

Market position

Day range

Current $2.80

52-week range

Current $2.80

Open
$2.71
Previous close
$2.74
Volume
1.33M
0.6× average
Average volume
2.21M
Average daily volume
Market cap
522.59M USD
Beta
0.23
Market reference 1
50-day average
$2.5193
+11.14% above average
200-day average
$2.1213
+32.00% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
120.46M USD
P/E (TTM)
-7.87×
P/B (TTM)
2.63×
P/S (TTM)
330.13×
EV / EBITDA
-7.04×
Earnings yield
-14.49%
Free cash flow yield
-31.89%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
96.78%
Operating margin
-3686.67%
Net margin
-2178.90%
Return on equity
-13.33%
Return on assets
-11.54%
Return on invested capital
-29.46%

Financial health

Debt / equity
0.06×
Current ratio
10.91×
Altman Z-score
12.17
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1622%-4467%-10556%-16645%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 95.86%Operating margin, FY2021: 59.61%Operating margin, FY2022: -3696.44%Operating margin, FY2023: -15122.70%Operating margin, FY2024: -10933.75%Operating margin, FY2025: -585.20%Net margin, FY2021: 58.95%Net margin, FY2022: -3604.66%Net margin, FY2023: -13351.79%Net margin, FY2024: -4670.14%Net margin, FY2025: -240.13%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 95.86%. Operating margin FY2021 59.61%. Operating margin FY2022 -3696.44%. Operating margin FY2023 -15122.70%. Operating margin FY2024 -10933.75%. Operating margin FY2025 -585.20%. Net margin FY2021 58.95%. Net margin FY2022 -3604.66%. Net margin FY2023 -13351.79%. Net margin FY2024 -4670.14%. Net margin FY2025 -240.13%.

Income trends

Revenue

7.25M USD+1181.27%

Operating income

−42.44M USD+31.42%

Net income

−17.41M USD+34.12%
Income trends across reported periods235.41M USD127.3M USD19.2M USD−88.91M USDRevenue, FY2021: 208.38M USDRevenue, FY2022: 1.5M USDRevenue, FY2023: 392K USDRevenue, FY2024: 566K USDRevenue, FY2025: 7.25M USDOperating income, FY2021: 124.21M USDOperating income, FY2022: −55.55M USDOperating income, FY2023: −59.28M USDOperating income, FY2024: −61.89M USDOperating income, FY2025: −42.44M USDNet income, FY2021: 122.83M USDNet income, FY2022: −54.17M USDNet income, FY2023: −52.34M USDNet income, FY2024: −26.43M USDNet income, FY2025: −17.41M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 208.38M USD. Revenue FY2022 1.5M USD. Revenue FY2023 392K USD. Revenue FY2024 566K USD. Revenue FY2025 7.25M USD. Operating income FY2021 124.21M USD. Operating income FY2022 −55.55M USD. Operating income FY2023 −59.28M USD. Operating income FY2024 −61.89M USD. Operating income FY2025 −42.44M USD. Net income FY2021 122.83M USD. Net income FY2022 −54.17M USD. Net income FY2023 −52.34M USD. Net income FY2024 −26.43M USD. Net income FY2025 −17.41M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue7.25M USD566K USD392K USD1.5M USD208.38M USD
Cost of goods sold300K USD————
Gross profit6.95M USD566K USD392K USD1.5M USD208.38M USD
Research and development25.58M USD36.77M USD28.59M USD24.62M USD46.94M USD
Selling, general, and administrative24.11M USD25.68M USD29.59M USD32.43M USD37.23M USD
Operating expenses49.39M USD62.45M USD59.67M USD57.05M USD84.17M USD
Interest income—3.9M USD4.9M USD——
Depreciation and amortization300K USD613K USD568K USD1.38M USD237.08K USD
Operating income−42.44M USD−61.89M USD−59.28M USD−55.55M USD124.21M USD
Net income−17.41M USD−26.43M USD−52.34M USD−54.17M USD122.83M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 3 misses, 2 met estimates
Average EPS surprise
+36.76%
11 comparable reports
Latest EPS result
-0.08
Estimate -0.12 · Beat by 30.43%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.1-0-0.11-0.21Q1 '25BeatQ2 '25MetQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -0.13, estimate -0.16, surprise +18.75%, Beat. Q2 2025, reported May 13, 2025: actual -0.14, estimate -0.14, surprise 0.00%, Met estimate. Q3 2025, reported Aug 13, 2025: actual -0.06, estimate -0.16, surprise +62.50%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.17, estimate -0.15, surprise -13.33%, Miss. Q1 2026, reported Mar 18, 2026: actual 0.06, estimate -0.1, surprise +160.00%, Beat. Q2 2026, reported May 12, 2026: actual -0.12, estimate -0.12, surprise 0.00%, Met estimate. Q3 2026, reported Aug 13, 2026: actual -0.08, estimate -0.115, surprise +30.43%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.09, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates6.77M4.52M2.27M17.24KQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26EstimateQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 76K USD, estimate 100K USD, surprise -24.00%, Miss. Q2 2025, reported May 13, 2025: actual 130K USD, estimate 42.5K USD, surprise +205.88%, Beat. Q3 2025, reported Aug 13, 2025: actual 6.27M USD, estimate 61.33K USD, surprise +10126.64%, Beat. Q4 2025, reported Nov 12, 2025: actual 132K USD, estimate 62.6K USD, surprise +110.86%, Beat. Q1 2026, reported Mar 18, 2026: actual 718K USD, estimate 78.25K USD, surprise +817.57%, Beat. Q2 2026, reported May 12, 2026: actual —, estimate 56.67K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual 733K USD, estimate 21.43K USD, surprise +3320.60%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate 20.29K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$5.50

96.43% upside
Past 12 months12-month forecastHigh $7.00Average $5.50Low $4.00

Rating distribution

14 ratings
Strong buy00%
Buy1179%
Hold321%
Sell00%
Strong sell00%

Recent analyst actions

6 institutions
B. Riley SecuritiesmaintainBuy

OVID news

zacks.com

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read source
zacks.com

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.

Read source
globenewswire.com

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today…

Read source
zacks.com

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read source
defenseworld.net

Ally Bridge Group NY LLC Has $6.26 Million Position in Ovid Therapeutics $OVID

Ally Bridge Group NY LLC raised its stake in Ovid Therapeutics (NASDAQ: OVID) by 57.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm…

Read source
defenseworld.net

ADAR1 Capital Management LLC Acquires 259,113 Shares of Ovid Therapeutics $OVID

ADAR1 Capital Management LLC grew its holdings in Ovid Therapeutics (NASDAQ: OVID) by 6.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned…

Read source

OVID peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding OVID

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
14.15M
Weight
0.12%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
12.55M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
10.48M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
4.34M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.47M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.9M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.44M
Weight
0.10%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
1.34M
Weight
0.02%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%

Continue in GoAI

Research OVID

research.disclaimer